Pharmacokinetics of azithromycin administered alone and with atovaquone in human immunodeficiency virus-infected children

Leock Y. Ngo, Ram Yogev, Wayne M. Dankner, Walter T. Hughes, Sandra Burchett, Jing Xu, Brian Sadler, Jashvant D. Unadkat*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Abstract

To evaluate if atovaquone (ATQ) interacts pharmacokinetically with azithromycin (AZ) in human immunodeficiency virus-infected children, 10 subjects (ages, 4 to 13 years) were randomized in a crossover study to receive AZ (5 mg/kg/day) alone (ALONE) or AZ (5 mg/kg/day) and ATQ (30 mg/kg/day) simultaneously (SIM) prior to receiving AZ and ATQ staggered by 12 h. Despite a lack of significant difference in the mean AZ pharmacokinetic parameters, the steady-state values of AZ's area under the concentration- time curve from 0 to 24 h and maximum concentration in serum were consistently lower (n = 7 of 7) for the SIM regimen than they were for the ALONE regimen. A larger study will be required to determine if ATQ affects AZ pharmacokinetics and efficacy in a clinically significant manner.

Original languageEnglish (US)
Pages (from-to)1516-1519
Number of pages4
JournalAntimicrobial agents and chemotherapy
Volume43
Issue number6
DOIs
StatePublished - Jun 1999

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Pharmacokinetics of azithromycin administered alone and with atovaquone in human immunodeficiency virus-infected children'. Together they form a unique fingerprint.

Cite this